AnacrotineCAS# 5096-49-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 5096-49-1 | SDF | Download SDF |
| PubChem ID | 5281720 | Appearance | Powder |
| Formula | C18H25NO6 | M.Wt | 351.40 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC=C1CC(C(C(=O)OCC2=CCN3C2C(C(C3)O)OC1=O)(C)O)C | ||
| Standard InChIKey | NPYPUYCITBTPSF-TZCAYXSXSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Anacrotine produces much more severe lung damage than most other pyrrolizidine alkaloids. |
Anacrotine Dilution Calculator
Anacrotine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | 56.9152 mL | 71.144 mL |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | 11.383 mL | 14.2288 mL |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL | 5.6915 mL | 7.1144 mL |
| 50 mM | 0.0569 mL | 0.2846 mL | 0.5692 mL | 1.1383 mL | 1.4229 mL |
| 100 mM | 0.0285 mL | 0.1423 mL | 0.2846 mL | 0.5692 mL | 0.7114 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Carminomycin
Catalog No.:BCC6379
CAS No.:50935-04-1, 39472-31-6
- Verminoside
Catalog No.:BCN5625
CAS No.:50932-19-9
- Mizoribine
Catalog No.:BCC4454
CAS No.:50924-49-7
- Bombinakinin M
Catalog No.:BCC5904
CAS No.:509151-65-9
- Boc-D-Arg(NO2)-OH
Catalog No.:BCC2610
CAS No.:50913-12-7
- 2-Amino-3,5-dibromobenzaldehyde
Catalog No.:BCC8523
CAS No.:50910-55-9
- IRAK-1-4 Inhibitor I
Catalog No.:BCC1659
CAS No.:509093-47-4
- 1beta-Hydroxytorilin
Catalog No.:BCN7095
CAS No.:509078-16-4
- Taiwanhomoflavone B
Catalog No.:BCN5624
CAS No.:509077-91-2
- Nemorensine
Catalog No.:BCN2099
CAS No.:50906-96-2
- Toxyloxanthone D
Catalog No.:BCN3070
CAS No.:50906-62-2
- Arteannuin B
Catalog No.:BCN5623
CAS No.:50906-56-4
- Crotanecine
Catalog No.:BCN1963
CAS No.:5096-50-4
- Canadine
Catalog No.:BCN5626
CAS No.:5096-57-1
- N-Methylcoclaurine
Catalog No.:BCN7079
CAS No.:5096-70-8
- 16-Methoxystrychnidin-10-One
Catalog No.:BCN8472
CAS No.:5096-72-0
- 7ACC1
Catalog No.:BCC5553
CAS No.:50995-74-9
- Pronethalol hydrochloride
Catalog No.:BCC5678
CAS No.:51-02-5
- Procaine HCl
Catalog No.:BCC5072
CAS No.:51-05-8
- Benzimidazole
Catalog No.:BCC8847
CAS No.:51-17-2
- Fluorouracil (Adrucil)
Catalog No.:BCC2135
CAS No.:51-21-8
- Tiratricol
Catalog No.:BCC4738
CAS No.:51-24-1
- Isoprenaline HCl
Catalog No.:BCC4328
CAS No.:51-30-9
- Scopolamine
Catalog No.:BCN5045
CAS No.:51-34-3
Metabolism and toxicity of anacrotine, a pyrrolizidine alkaloid, in rats.[Pubmed:3652286]
Chem Biol Interact. 1987;63(1):91-104.
The effects of Anacrotine, a pyrrolizidine alkaloid (PA) which has the structure of senecionine with an additional 6-hydroxy group, have been investigated in weanling male rats. When Anacrotine was given i.p. (100 mg/kg), pyrrolic metabolites reached a peak level in the liver during the first 0.5 h, then fell rapidly to a lower level which subsequently declined more slowly. Pyrrolic metabolites accumulated in the lungs during the first hour to a level which then remained relatively steady for at least 4 h. The lung level of pyrrolic metabolites after 2 h was about 39% of the liver level, compared with 16% in rats given senecionine. Anacrotine caused acute centrilobular necrosis and congestion of the liver when 125 mg/kg or more was given i.p., but oral doses (up to 180 mg/kg) caused relatively little liver necrosis. Enlarged hepatocytes developed during ensuing weeks, but these were moderate compared with the bizarre giant cells often associated with pyrrolizidine intoxication. In contrast, Anacrotine produced much more severe lung damage than most other pyrrolizidine alkaloids. The lungs were affected by i.p. or oral doses well below those needed to produce acute liver damage. Pulmonary congestion and oedema, extensive necrosis of the pulmonary endothelium, and thickening of alveolar septae, developed within 2 days after dosing. After single i.p. doses of 60 mg/kg or more progressive consolidation of lung tissue often led to death after 2-5 weeks. Hearts showed myocardial necrosis of the right ventricular wall. DehydroAnacrotine, the putative reactive pyrrolic metabolite of Anacrotine, given i.v. to rats, caused dose-related chronic lung and heart damage identical to that produced by Anacrotine, but after lower doses (6-27 mg/kg); larger amounts caused acute lung damage. It is suggested that the severe lung damage in animals given Anacrotine is due to dehydroAnacrotine, formed in the liver. This metabolite is more stable than the pyrrolic derivatives of most other pyrrolizidine alkaloids, and it is thus able to reach the lungs in relatively large amounts.
